Literature DB >> 27105398

A Young Woman With Recurrent Gestational Hypercalcemia and Acute Pancreatitis Caused by CYP24A1 Deficiency.

Gina N Woods1, Alec Saitman2, Hanlin Gao3, Nigel J Clarke4, Robert L Fitzgerald2, Nai-Wen Chi5.   

Abstract

The CYP24A1 gene encodes a mitochondrial 24-hydroxylase that inactivates 1,25(OH)2 D. Loss-of-function mutations in CYP24A1 cause hypercalcemia, nephrolithiasis and nephrocalcinosis. We describe a woman with CYP24A1 deficiency and recurrent gestational hypercalcemia. Her first pregnancy, at age 20, resulted with the intrauterine demise of twin fetuses. Postpartum, she developed severe hypercalcemia (14 mg/dL), altered mental status, and acute pancreatitis. Her PTH was suppressed (6 pg/mL) and her 1,25(OH)2 D was elevated (165 and 195 pg/mL on postpartum day 1 and 5, respectively). Between one and three months postpartum, her serum calcium decreased from 11.4 to 10.2 mg/dL while her 1,25(OH)2 D level decreased from 83 to 24 pg/mL. Her 24-hour urine calcium was 277 mg. Six months postpartum, she became pregnant again. At 14 weeks, her albumin-corrected calcium level was 10.4 mg/dL and her 1,25(OH)2 D level exceeded 200 pg/mL. To establish the diagnosis of CYP24A1 deficiency, we showed her 24,25(OH)2 D level to be undetectable (<2 ng/mL). Exon sequencing of the CYP24A1 gene revealed a homozygous, 8-nucleotide deletion in exon 8, causing an S334V substitution and premature termination due to a frame shift (c.999_1006del, p.Ser334Valfs*9). To prevent hypercalcemia, she was advised to discontinue prenatal vitamins, avoid sun exposure and calcium-rich foods, and start omeprazole and a calcium binder (250 mg K-Phos-neutral with meals). Despite these measures, both hypercalcemia (11.5 mg/dL) and acute pancreatitis recurred. Labor was induced and a healthy, normocalcemic boy was delivered. In the absence of lactation, maternal hypercalcemia resolved within 2 months. This report shows that CYP24A1-deficient subjects may be normocalcemic at baseline. Hypercalcemia may be unmasked by pregnancy through the routine use of calciferol-containing prenatal vitamins, increased 1-alpha hydroxylation of VitD by the placenta and maternal kidney, and production of PTHrP by the uteroplacental unit. CYP24A1 deficiency should be considered in patients with unexplained vitamin D-mediated hypercalcemia.
© 2016 American Society for Bone and Mineral Research. © 2016 American Society for Bone and Mineral Research.

Entities:  

Keywords:  CYP24A1; HYPERCALCEMIA; PANCREATITIS; VITAMIN D

Mesh:

Substances:

Year:  2016        PMID: 27105398      PMCID: PMC5071127          DOI: 10.1002/jbmr.2859

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  26 in total

1.  The pathogenesis of idiopathic hypercalcemia in infancy.

Authors:  T STAPLETON; W B MACDONALD; R LIGHTWOOD
Journal:  Am J Clin Nutr       Date:  1957 Sep-Oct       Impact factor: 7.045

2.  Idiopathic hypercalcaemia in infants.

Authors:  R LIGHTWOOD; T STAPLETON
Journal:  Lancet       Date:  1953-08-01       Impact factor: 79.321

Review 3.  Primary hyperparathyroidism during pregnancy.

Authors:  Vincent Dochez; Guillaume Ducarme
Journal:  Arch Gynecol Obstet       Date:  2014-11-04       Impact factor: 2.344

Review 4.  Molecular evolution of P450 superfamily and P450-containing monooxygenase systems.

Authors:  K N Degtyarenko; A I Archakov
Journal:  FEBS Lett       Date:  1993-10-11       Impact factor: 4.124

5.  Clinical utility of simultaneous quantitation of 25-hydroxyvitamin D and 24,25-dihydroxyvitamin D by LC-MS/MS involving derivatization with DMEQ-TAD.

Authors:  Martin Kaufmann; J Christopher Gallagher; Munro Peacock; Karl-Peter Schlingmann; Martin Konrad; Hector F DeLuca; Rita Sigueiro; Borja Lopez; Antonio Mourino; Miguel Maestro; René St-Arnaud; Joel S Finkelstein; Donald P Cooper; Glenville Jones
Journal:  J Clin Endocrinol Metab       Date:  2014-03-26       Impact factor: 5.958

Review 6.  Nonsense-mediated decay in genetic disease: friend or foe?

Authors:  Jake N Miller; David A Pearce
Journal:  Mutat Res Rev Mutat Res       Date:  2014-05-28       Impact factor: 5.657

7.  Studies of the hypercalcaemia of sarcoidosis: effect of steroids and exogenous vitamin D3 on the circulating concentrations of 1,25-dihydroxy vitamin D3.

Authors:  L M Sandler; C G Winearls; L J Fraher; T L Clemens; R Smith; J L O'Riordan
Journal:  Q J Med       Date:  1984

Review 8.  Parathyroid disorders of pregnancy.

Authors:  J H Mestman
Journal:  Semin Perinatol       Date:  1998-12       Impact factor: 3.300

9.  Severe hypercalcemic crisis in an infant with idiopathic infantile hypercalcemia caused by mutation in CYP24A1 gene.

Authors:  Filip Fencl; Květa Bláhová; Karl Peter Schlingmann; Martin Konrad; Tomáš Seeman
Journal:  Eur J Pediatr       Date:  2012-09-22       Impact factor: 3.183

10.  Parathyroid hormone-related protein (PTHrP) mRNA splicing and parathyroid hormone/PTHrP receptor mRNA expression in human placenta and fetal membranes.

Authors:  N E Curtis; R J Thomas; M T Gillespie; R G King; G E Rice; M E Wlodek
Journal:  J Mol Endocrinol       Date:  1998-10       Impact factor: 5.098

View more
  10 in total

Review 1.  Hypercalcemia in Pregnancy Due to CYP24A1 Mutations: Case Report and Review of the Literature.

Authors:  Stefan Pilz; Verena Theiler-Schwetz; Pawel Pludowski; Sieglinde Zelzer; Andreas Meinitzer; Spyridon N Karras; Waldemar Misiorowski; Armin Zittermann; Winfried März; Christian Trummer
Journal:  Nutrients       Date:  2022-06-17       Impact factor: 6.706

Review 2.  Vitamin D and Pancreatitis: A Narrative Review of Current Evidence.

Authors:  Fei Cai; Cheng Hu; Chan-Juan Chen; Yuan-Ping Han; Zi-Qi Lin; Li-Hui Deng; Qing Xia
Journal:  Nutrients       Date:  2022-05-18       Impact factor: 6.706

Review 3.  Parathyroid Disease in Pregnancy and Lactation: A Narrative Review of the Literature.

Authors:  Elena Tsourdi; Athanasios D Anastasilakis
Journal:  Biomedicines       Date:  2021-04-26

4.  Outcomes Following Treatment of Maternal Hypercalcemia Due to CYP24A1 Pathogenic Variants.

Authors:  Lucy McBride; Christine Houlihan; Catherine Quinlan; Betty Messazos; Zornitza Stark; Amy Crosthwaite
Journal:  Kidney Int Rep       Date:  2019-03-08

5.  Three Sisters With Heterozygous Gene Variants of CYP24A1: Maternal Hypercalcemia, New-Onset Hypertension, and Neonatal Hypoglycemia.

Authors:  Fredric Hedberg; Christina Pilo; Johan Wikner; Ove Törring; Jan Calissendorff
Journal:  J Endocr Soc       Date:  2018-12-17

6.  High Prevalence of Kidney Cysts in Patients With CYP24A1 Deficiency.

Authors:  Christian Hanna; Theodora A Potretzke; Andrea G Cogal; Yaman G Mkhaimer; Peter J Tebben; Vicente E Torres; John C Lieske; Peter C Harris; David J Sas; Dawn S Milliner; Fouad T Chebib
Journal:  Kidney Int Rep       Date:  2021-05-12

7.  Biallelic CYP24A1 variants presenting during pregnancy: clinical and biochemical phenotypes.

Authors:  Tomás P Griffin; Caroline M Joyce; Sumaya Alkanderi; Liam M Blake; Derek T O'Keeffe; Delia Bogdanet; Md Nahidul Islam; Michael C Dennedy; John E Gillan; John J Morrison; Timothy O'Brien; John A Sayer; Marcia Bell; Paula M O'Shea
Journal:  Endocr Connect       Date:  2020-06       Impact factor: 3.335

8.  Juvenile onset IIH and CYP24A1 mutations.

Authors:  Karl P Schlingmann; Walburga Cassar; Martin Konrad
Journal:  Bone Rep       Date:  2018-06-21

9.  Intractable hypercalcaemia during pregnancy and the postpartum secondary to pathogenic variants in CYP24A1.

Authors:  Nirusha Arnold; Victor O'Toole; Tien Huynh; Howard C Smith; Catherine Luxford; Roderick Clifton-Bligh; Creswell J Eastman
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2019-11-21

10.  24-Hydroxylase Deficiency Due to CYP24A1 Sequence Variants: Comparison With Other Vitamin D-mediated Hypercalcemia Disorders.

Authors:  Sarah M Azer; Lisa E Vaughan; Peter J Tebben; David J Sas
Journal:  J Endocr Soc       Date:  2021-07-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.